Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis
21 nov. 2017 08h00 HE
|
Menlo Therapeutics Inc.
REDWOOD CITY, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc., a late-stage biopharmaceutical company developing a neurokinin 1 (NK‐1) receptor antagonist (serlopitant) for the...